Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An engineered bispecific nanobody in tetrameric secretory IgA format confers broad neutralization against SARS-CoV-1&2 and most variants

9 Sept 2023

Abstract excerpt

SARS-CoV-2, a type of respiratory virus, has exerted a great impact on global health and economy over the past three years. Antibody-based therapy was initially successful but later failed due to the accumulation of mutations in the spike protein of the virus. Strategies that enable antibodies to resist virus escape are therefore of great significance. Here, we engineer a bispecific SARS-CoV-2 neutralizing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Respiratory viral infections research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37690653
DOI: 10.1016/j.ijbiomac.2023.126817

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An engineered bispecific nanobody in tetrameric secretory IgA format confers broad neutralization against SARS-CoV-1&2 and most variantsPMID 37690653Read ↗

Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variantsSemantic proximity Read ↗

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administrationSemantic proximity Read ↗

Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster modelsSemantic proximity Read ↗

A Potent Bispecific Nanobody Protects hACE2 Mice Against SARS-CoV-2 Infection via Intranasal AdministrationSemantic proximity Read ↗

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of ConcernSemantic proximity Read ↗

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralizationSemantic proximity Read ↗

A bivalent spike-targeting nanobody with anti-sarbecovirus activitySemantic proximity Read ↗

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2Semantic proximity Read ↗

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2Semantic proximity Read ↗

A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variantsSemantic proximity Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.